In February 2021, the healthcare industry reported 85 deals worth $30 billion as compared to last 12-month average (February 2020 to January 2021) of 88 deals worth $17.3 billion.

ICON, a provider of outsourced development services to the biotechnology, pharmaceutical and medical device industries is set to acquire PRA Health Sciences, a contract research organisation engaged in providing outsourced clinical development and data solution services for approximately $12 billion; Jazz Pharmaceuticals, a biopharma company is set to acquire GW Pharmaceuticals, also a biopharma company for $7.2 billion and Horizon Therapeutics, a biopharma company is set to acquire Viela Bio, a biotech company specialised in discovery, development and commercialisation of novel treatments for autoimmune and severe inflammatory diseases for $3 billion are the three major deals which contributed 74 per cent of the total deal value in February 2021.

VC investments decreased by 34.7 per cent in Feb 2021, compared to Jan 2021

The healthcare industry reported 88 venture capital (VC) deals worth $3.2billion in February 2021, compared to the last 12-month average (February 2020 to January 2021) of 125 deals worth $3.5 billion.

Centessa Pharmaceuticals, a biopharma company raising $250 million in series A round of financing; Clover Biopharmaceuticals, a clinical-stage biotechnology company raising $230 million in series C  round of financing to support the continued development and expansion of its pipeline of protein-based vaccines and biologic cancer therapies; Vividion Therapeutics, a biotech company raising $135 million in series C round of financing to fuel broad pipeline of precision oncology and immunology programs are the major VC deals reported in February 2021.